Investigation of the therapeutic value of angiogenesis inhibitors is one of the most dynamic, highly visible, and entrepreneurial areas of cancer research, and many cancer care facilities are poised to participate in clinical trials of these agents. Angiogenesis Inhibition in Cancer Therapy is a new study published by Decision Resources, Inc., that examines this innovative therapeutic approach and provides market estimates based on several scenarios for these anticancer agents. To date, a number of angiogenesis inhibitors have reached clinical trials and can be expected to reach the cancer marketplace during the course of our 1999-2009 study period.
The matrix metalloproteinase (MMP) inhibitors are the most developed of the angiogenesis inhibitor classes, with several agents (namely, marimastat and prinomastat) now in Phase III trials; this class also includes natural cartilage extracts thought to inhibit MMPs (Neovastat and Benefin). Several receptor tyrosine kinase inhibitors (e.g., SU5416) are also advancing quickly through clinical trials. Both of these drug classes offer the advantage of oral bioavailability. Other angiogenesis inhibitors now in clinical trials reduce growth factor expression or interaction with its receptor (IM862, Angiozyme, rhuMAb-VEGF), interfere with integrin signaling (Vitaxin, cilengitide), or work by novel or as yet unidentified mechanisms (combretastatin, TNP-470, CAI, CM101, squalamine, and thalidomide). Also noteworthy among these agents are EntreMed's Endostatin and Angiostatin; both of these endogenous inhibitors of angiogenesis have just entered clinical trials.
Because no angiogenesis inhibitors have reached the marketplace, a number of scenarios are likely: conservatively, we foresee that the total U.S., European, and Japanese market for angiogenesis inhibitors could total $530 million in 2004 and $6.4 billion in 2009. Assuming a more aggressive scenario, we foresee that rapid introduction and widespread use of the MMPIs and signal transduction inhibitors could increase the 2004 market to $2.7 billion, and that sales of angiogenesis inhibitors could surpass $12 billion by 2009 if these agents perform in clinical trials as well as they have in preclinical models.
Angiogenesis Inhibition in Cancer Therapy is part of Onkos, a multiclient service that evaluates the commercial potential of drugs in research and development to treat cancer.
Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or firstname.lastname@example.org (e-mail). In Europe, contact Ms. Francoise, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org (e-mail). http://www.dresources.com
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for nearly 30 years, assessing industry trends in the international health care and pharmaceutical industries. Drawing on a closely linked international network of experts, Decision Resources offers its clients the most comprehensive analyses of therapy markets available.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-487-3753,